•  
  •  
 

Abstract

Introduction. The Socal and Hasford scores developed before the era of tirosine kinase inhibitor (TKI) therapy to provide predictions and prognosis for the results of therapy for chronic myeloid leukemia patients (CML). Until now the superiority of Socal and Hasford scores is still debated in predicting the results of therapy in the era of TKI. Imatinib mesylat is a first line TKI in the treatment of CML. This study aims to determine the superior predictive score in predicting hematological and molecular response of patients treated with imatinib mesylate. Methods. A survey study was conducted with data taken retrospectively from medical records. Subjects were chronic phase LGK patients who had at least been given imatinib mesylate therapy for 12 months. Calculation of Socal and Hasford scores was carried out based on patient data when first receiving Imatinib. To see the difference in distribution between the two scores, a marginal homogeneity statistic was used. To see the process of changing the response of patients treated with Imatinib, a suitability test using chi-square and Fischer was conducted with a significant p value, p 0,05. Conclusion. There was no significant difference between Hasford and Socal scores in predicting hematological responses and molecular responses of chronic CML patients. Socal scores and Hasford scores can be used to predict hematological and molecular responses in chronic CML patients treated with imatinib mesylate.

Bahasa Abstract

Pendahuluan. Skor Sokal dan Hasford berkembang sebelum era terapi tirosine kinase inhibitor (TKI) untuk memberikan prediksi dan prognosis hasil terapi pasien leukemia granulositik kronis (LGK). Hingga saat ini, keunggulan skor Sokal dan Hasford masih diperdebatkan dalam memprediksi hasil terapi di era TKI. Imatinib mesylate merupakan TKI lini pertama dalam terapi LGK. Penelitian ini bertujuan untuk mengetahui skor prediktif yang lebih unggul dalam memprediksi respons hematologi maupun respons molekular pasien yang diterapi dengan imatinib mesylate. Metode. Penelitian ini merupakan penelitian survei, data yang diambil secara retrospektif dari rekam medis. Sampel penelitian adalah pasien LGK fase kronis yang sekurang-kurangnya telah mendapat terapi imatinib mesylate selama 12 bulan. Perhitungan skor Sokal maupun Hasford dilakukan berdasarkan data pasien pada saat mendapat imatinib pertama kali. Untuk melihat perbedaan distribusi antara kedua skor, digunakan uji statistik marginal homogenity. Untuk melihat proses perubahan respons pada pasien yang diobati dengan imatinib dilakukan uji kesesuaian menggunakan chi-square dan fischer dengan nilai p signifikan yaitu p 0,05. Simpulan. Tidak ada perbedaan antara skor Hasford dan skor Sokal dalam memprediksi respons hematologi maupun respons molekular pasien LGK kronis. Skor Sokal maupun skor Hasford dapat digunakan untuk memprediksi respons hematologi maupun respons molekular pada pasien LGK fase kronis yang diterapi dengan imatinib mesylate.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.